-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Werewolf Therapeutics (NASDAQ:HOWL) Trading Down 2.7%
Werewolf Therapeutics (NASDAQ:HOWL) Trading Down 2.7%
Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Rating) fell 2.7% on Tuesday . The stock traded as low as $3.68 and last traded at $4.00. 186,214 shares were traded during trading, a decline of 77% from the average session volume of 807,911 shares. The stock had previously closed at $4.11.
Analyst Ratings Changes
Separately, EF Hutton Acquisition Co. I initiated coverage on shares of Werewolf Therapeutics in a research report on Monday, December 5th. They set a "buy" rating and a $8.30 price target on the stock.
Get Werewolf Therapeutics alerts:Werewolf Therapeutics Stock Down 2.7 %
The stock's 50-day simple moving average is $2.41 and its 200 day simple moving average is $3.84. The company has a market cap of $123 million, a price-to-earnings ratio of -1.86 and a beta of -0.86.
Werewolf Therapeutics (NASDAQ:HOWL – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.20. The company had revenue of $4.97 million during the quarter, compared to analyst estimates of $6.10 million. On average, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -2.04 EPS for the current fiscal year.Insider Transactions at Werewolf Therapeutics
In other Werewolf Therapeutics news, Director Ra Capital Management, L.P. purchased 1,853,000 shares of Werewolf Therapeutics stock in a transaction dated Friday, January 6th. The shares were acquired at an average price of $2.21 per share, with a total value of $4,095,130.00. Following the completion of the transaction, the director now owns 5,701,056 shares of the company's stock, valued at $12,599,333.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 62.70% of the company's stock.
Institutional Trading of Werewolf Therapeutics
Several hedge funds have recently made changes to their positions in the business. Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter worth approximately $45,000. Bailard Inc. purchased a new position in Werewolf Therapeutics in the second quarter valued at approximately $87,000. Millennium Management LLC increased its stake in Werewolf Therapeutics by 487.1% in the second quarter. Millennium Management LLC now owns 248,917 shares of the company's stock valued at $1,018,000 after purchasing an additional 206,516 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Werewolf Therapeutics by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 68,338 shares of the company's stock valued at $301,000 after purchasing an additional 3,555 shares during the last quarter. Finally, Evercore Wealth Management LLC increased its stake in Werewolf Therapeutics by 116.3% in the first quarter. Evercore Wealth Management LLC now owns 46,500 shares of the company's stock valued at $205,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 68.17% of the company's stock.
About Werewolf Therapeutics
(Get Rating)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Stories
- Get a free copy of the StockNews.com research report on Werewolf Therapeutics (HOWL)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
周二,狼人治疗公司(纳斯达克代码:HOWL-GET评级)的股价下跌了2.7%。该股最低交易价格为3.68美元,最后报4.00美元。当日成交量为186,214股,较当日平均成交量807,911股减少77%。该股此前收盘价为4.11美元。
分析师评级发生变化
另外,EF Hutton Acquisition Co.I在12月5日(星期一)的一份研究报告中启动了对狼人治疗公司股票的报道。他们为该股设定了“买入”评级和8.30美元的目标价。
到达狼人治疗学警报:狼人治疗公司股价下跌2.7%
该股的50日简单移动均线切入位为2.41美元,200日简单移动均线切入位为3.84美元。该公司市值为1.23亿美元,市盈率为-1.86倍,贝塔系数为-0.86。
狼人治疗公司(纳斯达克:Howl-Get Rating)最近一次公布财报是在11月10日(星期四)。该公司公布了该季度每股收益(0.40美元),比分析师普遍预期的(0.60美元)高出0.20美元。该公司本季度营收为497万美元,而分析师预期为610万美元。卖方分析师平均预计,狼人治疗公司本财年每股收益将为2.04欧元。狼人治疗公司的内幕交易
在狼人治疗公司的其他新闻方面,董事Ra Capital Management,L.P.在一笔日期为1月6日星期五的交易中购买了1,853,000股狼人治疗公司的股票。这些股票是以每股2.21美元的平均价格收购的,总价值为4,095,130.00美元。交易完成后,董事现在拥有5701,056股该公司的股票,价值12,599,333.76美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。公司内部人士持有该公司62.70%的股份。
狼人疗法的制度性交易
几家对冲基金最近改变了他们在该业务中的头寸。Y Intercept Hong Kong Ltd在第二季度购买了狼人治疗公司的新股,价值约45,000美元。Bailard Inc.在第二季度购买了狼人治疗公司的一个新头寸,价值约为8.7万美元。千禧管理有限责任公司在第二季度增持了487.1%的狼人治疗公司的股份。Millennium Management LLC在上个季度额外购买了206,516股后,现在拥有248,917股该公司的股票,价值1,018,000美元。纽约梅隆银行第一季度增持狼人治疗公司5.5%的股份。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有68,338股该公司股票,价值301,000美元,此前该公司在上一季度又购买了3,555股。最后,Evercore Wealth Management LLC在第一季度增持了116.3%的狼人治疗公司的股份。Evercore Wealth Management LLC在上个季度额外购买了25,000股后,现在拥有46,500股该公司股票,价值20.5万美元。机构投资者和对冲基金持有该公司68.17%的股票。
关于狼人疗法
(获取评级)
狼人治疗公司是一家生物制药公司,该公司开发的疗法旨在刺激人体免疫系统治疗癌症。该公司通过其专有的捕食者平台,设计有条件激活的分子,刺激适应性和先天免疫,以解决传统促炎免疫疗法的局限性。
专题报道
- 免费获取StockNews.com关于狼人治疗的研究报告(Howl)
- Verizon,Charge在过去的一个月里趋势更高:他们现在购买吗?
- 股利之王Sysco:逢低买入
- 天才集团股票1600%的涨幅合理吗?
- 在进一步审查后,投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖出另一个收购机会吗?
接受《狼人治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对狼人治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧